New Antiplatelet Strategies in Atherothrombosis and Their Indications

European Journal of Vascular and Endovascular Surgery

Volumn 34, Issue 1, 2007, Pages 10-17

  Fontana, P ^a   Reny, J L ^b  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b Centre Hospitalier Beziers   (France)

Author keywords

Antiplatelet agents; Aspirin; Atherothrombosis; Clopidogrel

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; CYCLOOXYGENASE 1; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; METOPROLOL; NEW DRUG; PHOSPHODIESTERASE INHIBITOR; PICOTAMIDE; PLACEBO; PRASUGREL; S 18886; STREPTOKINASE; THIENOPYRIDINE DERIVATIVE; THROMBOXANE RECEPTOR BLOCKING AGENT; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ARTERY THROMBOSIS; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME INHIBITION; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; META ANALYSIS; MONOTHERAPY; NEUTROPENIA; OPTIMAL DRUG DOSE; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RISK REDUCTION; SECONDARY PREVENTION; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; THROMBOCYTE FUNCTION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSLUMINAL CORONARY ANGIOPLASTY;

EMBOLISM, CHOLESTEROL; HUMANS; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES; PROGRAM EVALUATION;

EID: 34249856499     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1016/j.ejvs.2007.01.004     Document Type: Article

References (58)

1. Monroe D.M., Hoffman M., and Roberts H.R. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 22 9 (Sep 1 2002) 1381-1389
2. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 2 (Jan 14 1999) 115-126
3. Phillips D.R., Conley P.B., Sinha U., and Andre P. Therapeutic approaches in arterial thrombosis. J Thromb Haemost 3 8 (Aug 2005) 1577-1589
4. Yeh E.T., and Khan B.V. The potential role of antiplatelet agents in modulating inflammatory markers in atherothrombosis. J Thromb Haemost (Sep 8 2006)
5. Patrono C., Garcia Rodriguez L.A., Landolfi R., and Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353 22 (Dec 1 2005) 2373-2383
6. Patrono C., Coller B., FitzGerald G.A., Hirsh J., and Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (Sep 2004) 234S-264S
7. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. J Am Coll Cardiol 12 6 Suppl. A (Dec 1988) 3A-13A
8. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 7329 (Jan 12 2002) 71-86
9. Smith Jr. S.C., Allen J., Blair S.N., Bonow R.O., Brass L.M., Fonarow G.C., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113 19 (May 16 2006) 2363-2372
10. Silber S., Albertsson P., Aviles F.F., Camici P.G., Colombo A., Hamm C., et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 26 8 (Apr 2005) 804-847
11. Criqui M.H., Langer R.D., Fronek A., Feigelson H.S., Klauber M.R., McCann T.J., et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 326 6 (Feb 6 1992) 381-386
12. Berger J.S., Roncaglioni M.C., Avanzini F., Pangrazzi I., Tognoni G., and Brown D.L. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 295 3 (Jan 18 2006) 306-313
13. Hackam D.G., and Eikelboom J.W. Antithrombotic therapy for peripheral arterial disease. Heart (Oct 11 2006) 10.1136/hrt.2006.102350
14. Hirsch A.T., Haskal Z.J., Hertzer N.R., Bakal C.W., Creager M.A., Halperin J.L., et al. ACC/AHA Guidelines for the Management of Patients with Peripheral Arterial Disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Associations for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease)-summary of recommendations. J Vasc Interv Radiol 17 9 (Sep 2006) 1383-1397 [quiz 1398]
15. Norgren L., Hiatt W.R., Dormandy J.A., Nehler M.R., Harris K.A., and Fowkes F.G. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 33 1 Suppl (2007) S1-S75
16. Lechat P., and Priollet P. Prevention of major ischemic events in lower limb arterial disease: does aspirin play a role?. J Mal Vasc 31 3 (Jul 2006) 129-134
17. Neri Serneri G.G., Coccheri S., Marubini E., and Violi F. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J 25 20 (Oct 2004) 1845-1852
18. Savi P., Herbert J.M., Pflieger A.M., Dol F., Delebassee D., Combalbert J., et al. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol 44 3 (Aug 4 1992) 527-532
19. Hollopeter G., Jantzen H.M., Vincent D., Li G., England L., Ramakrishnan V., et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409 6817 (Jan 11 2001) 202-207
20. Thebault J.J., Kieffer G., Lowe G.D., Nimmo W.S., and Cariou R. Repeated-dose pharmacodynamics of clopidogrel in healthy subjects. Semin Thromb Hemost 25 Suppl 2 (1999) 9-14
21. Cattaneo M. ADP receptors: inhibitory strategies for antiplatelet therapy. Drug News Perspect 19 5 (Jun 2006) 253-259
22. Patti G., Colonna G., Pasceri V., Pepe L.L., Montinaro A., and Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 111 16 (Apr 26 2005) 2099-2106
23. Cuisset T., Frere C., Quilici J., Morange P.E., Nait-Saidi L., Carvajal J., et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 48 7 (Oct 3 2006) 1339-1345
24. Montalescot G., Sideris G., Meuleman C., Bal-dit-Sollier C., Lellouche N., Steg P.G., et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 48 5 (Sep 5 2006) 931-938
25. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348 9038 (Nov 16 1996) 1329-1339
26. Hirsh J., and Bhatt D.L. Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies. Arch Intern Med 164 19 (Oct 25 2004) 2106-2110
27. Rothwell P.M. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet 365 9454 (Jan 8-14 2005) 176-186
28. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., and Fox K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 7 (Aug 16 2001) 494-502
29. Sabatine M.S., Cannon C.P., Gibson C.M., Lopez-Sendon J.L., Montalescot G., Theroux P., et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352 12 (Mar 24 2005) 1179-1189
30. Chen Z.M., Jiang L.X., Chen Y.P., Xie J.X., Pan H.C., Peto R., et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 9497 (Nov 5 2005) 1607-1621
31. Schomig A., Neumann F.J., Kastrati A., Schuhlen H., Blasini R., Hadamitzky M., et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 334 17 (Apr 25 1996) 1084-1089
32. Urban P., Macaya C., Rupprecht H.J., Kiemeneij F., Emanuelsson H., Fontanelli A., et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 98 20 (Nov 17 1998) 2126-2132
33. Leon M.B., Baim D.S., Popma J.J., Gordon P.C., Cutlip D.E., Ho K.K., et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 339 23 (Dec 3 1998) 1665-1671
34. Mehta S.R., Yusuf S., Peters R.J., Bertrand M.E., Lewis B.S., Natarajan M.K., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 9281 (Aug 18 2001) 527-533
35. Iakovou I., Schmidt T., Bonizzoni E., Ge L., Sangiorgi G.M., Stankovic G., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 17 (May 4 2005) 2126-2130
36. Diener H.C., Bogousslavsky J., Brass L.M., Cimminiello C., Csiba L., Kaste M., et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364 9431 (Jul 24 2004) 331-337
37. Jamieson D.G., Parekh A., and Ezekowitz M.D. Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents. J Cardiovasc Pharmacol Ther 10 3 (Sep 2005) 153-161
38. Lastilla M. Lacunar infarct. Clin Exp Hypertens 28 3-4 (Apr-May 2006) 205-215
39. Bhatt D.L., Fox K.A., Hacke W., Berger P.B., Black H.R., Boden W.E., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 16 (Apr 20 2006) 1706-1717
40. Pfeffer M.A., and Jarcho J.A. The charisma of subgroups and the subgroups of CHARISMA. N Engl J Med 354 16 (Apr 20 2006) 1744-1746
41. Ahrens I., Bode C., and Peter K. Inhibition of platelet activation and aggregation. Handb Exp Pharmacol 170 (2005) 443-462
42. Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group. Circulation 62 3 (Sep 1980) 449-461
43. Schaefer W.M., Koch K.C., Nowak B., Noth J., Buell U., and Weiss P.H. Dipyridamole/aspirin combination in secondary stroke prevention: effects on absolute myocardial blood flow and coronary vascular resistance. Int J Clin Pharmacol Ther 44 7 (Jul 2006) 319-325
44. Halkes P.H., van Gijn J., Kappelle L.J., Koudstaal P.J., and Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 367 9523 (May 20 2006) 1665-1673
45. Douglas Jr. J.S., Holmes Jr. D.R., Kereiakes D.J., Grines C.L., Block E., Ghazzal Z.M., et al. Coronary stent restenosis in patients treated with cilostazol. Circulation 112 18 (Nov 1 2005) 2826-2832
46. Thompson P.D., Zimet R., Forbes W.P., and Zhang P. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 90 12 (Dec 15 2002) 1314-1319
47. Chew D.P., Bhatt D.L., Sapp S., and Topol E.J. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 103 2 (Jan 16 2001) 201-206
48. Kastrati A., Mehilli J., Neumann F.J., Dotzer F., ten Berg J., Bollwein H., et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 295 13 (Apr 5 2006) 1531-1538
49. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial. Stroke 36 4 (Apr 2005) 880-890
50. Ciccone A., Abraha I., and Santilli I. Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke. Cochrane Database Syst Rev 4 (2006) CD005208
51. Gachet C. The platelet P2 receptors as molecular targets for old and new antiplatelet drugs. Pharmacol Ther 108 2 (Nov 2005) 180-192
52. Gaussem P., Reny J.L., Thalamas C., Chatelain N., Kroumova M., Jude B., et al. The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies. J Thromb Haemost 3 7 (Jul 2005) 1437-1445
53. Brass L.F., Zhu L., and Stalker T.J. Minding the gaps to promote thrombus growth and stability. J Clin Invest 115 12 (Dec 2005) 3385-3392
54. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 91 Suppl 5 (Dec 2005) v1-v52
55. Toni D., Chamorro A., Kaste M., Lees K., Wahlgren N.G., and Hacke W. Acute treatment of ischaemic stroke. European Stroke Initiative. Cerebrovasc Dis 17 Suppl 2 (2004) 30-46
56. Patrono C., Bachmann F., Baigent C., Bode C., De Caterina R., Charbonnier B., et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 25 2 (Jan 2004) 166-181
57. Sacco R.L., Adams R., Albers G., Alberts M.J., Benavente O., Furie K., et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 37 2 (Feb 2006) 577-617
58. Smith Jr. S.C., Feldman T.E., Hirshfeld Jr. J.W., Jacobs A.K., Kern M.J., King III S.B., et al. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 113 1 (Jan 3 2006) 156-175